How I treat acquired aplastic anemia

Area of Science:

• Hematology
• Internal Medicine
• Oncology

Background:

• Severe aplastic anemia (SAA) management has evolved significantly over 40 years.
• Advances include hematopoietic stem cell transplantation, immunosuppressive therapies, and supportive care.
• Despite progress, SAA patient management remains complex due to acute pancytopenia and long-term disease/treatment effects.

Purpose of the Study:

• To review key aspects of severe aplastic anemia management.
• To discuss differential diagnosis, first- and second-line therapy choices, and post-immunosuppression care.
• To integrate recent literature findings with extensive clinical and research experience.

Main Methods:

• Literature review of recent scientific publications.
• Analysis of personal and research protocol experience from the National Heart, Lung, and Blood Institute.
• Focus on bone marrow failure and severe aplastic anemia.

Main Results:

• Survival rates in SAA have markedly improved.
• Insights into SAA pathophysiology have practical clinical implications.
• Established approaches for differential diagnosis and therapeutic strategies.

Conclusions:

• SAA management requires careful consideration of acute and long-term patient needs.
• Therapeutic strategies are informed by pathophysiology, patient history, and treatment outcomes.
• Ongoing research and clinical experience continue to refine SAA patient care.